Уважаемые коллеги, доброго времени суток! Представляем вам нидерландское научное издание Open Dermatology Journal. Журнал имеет четвёртый квартиль, издаётся в Bentham Science Publishers B.V., находится в открытом доступе, его SJR за 2021 г. равен 0,173, электронный ISSN - 1874-3722, предметная область Дерматология. Вот так выглядит обложка:
Редактором является Грег Буркхарт, контактные данные - cgbakb@aol.com.
Это электронный журнал с открытым доступом, в котором публикуются оригинальные исследовательские статьи, обзоры / мини-обзоры, письма и тематические выпуски во всех областях экспериментальных и клинических исследований в области дерматологии, кожных заболеваний, косметической хирургии, дерматита, дерматопатологии, дерматологической хирургии, иммунодерматологии, детской дерматологии, теледерматологии и реконструктивной и косметической хирургии. Рецензируемый журнал Open Dermatology Journal является надежным источником актуальной информации о разработках в данной области. Акцент будет сделан на быстрой публикации качественных статей, которые будут в свободном доступе исследователям по всему миру.
Адрес издания - https://opendermatologyjournal.com/
Пример статьи, название - Efficacy of Autologous Serum Therapy in Chronic Urticaria, A Prospective Experimental Cohort Study. Заголовок (ABSTRACT)
Background:
Chronic Urticaria is one of the most therapeutic difficulties confronted by a dermatologist.
Objective:
The objective of this study is to estimate the efficacy of Autologous Serum Therapy (AST) in Chronic Urticaria patients and compare the efficacy of AST in each group of Autologous Serum Skin Test (ASST) positive and negative.
Methods:
A prospective study was conducted for the period of one year (July 2020 – July 2021) at Tishreen University Hospital. We enrolled 50 patients suffering from Chronic Urticaria. ASST was done for all patients before the treatment. We gave patients 9 injections of Autologous Serum intramuscularly once a week. The response to AST was evaluated by using Urticaria Total Severity Score (UTSS) before the treatment (0 weeks), after the treatment (9 weeks), and followed up for 3 months after the end of the treatment (21 weeks).
Results:
Between 50 patients, the sample was distributed equally in each group of ASST (positive and negative). 18 patients (36%) had an excellent response, 7 patients (14%) had a very good response, 11 patients (22%) had a good response, and 14 patients (28%) had no response. The treatment was effective in both ASST positive and negative groups, however, there was no significant relationship in response between the two groups.
There was a significant relationship between clinical response and severity of disease p-value = 0.04, the majority of excellent response cases (88.9%) had severe disease before the treatment.
Limitations:
The main limitations of our study were the lack of patients and the short follow-up period (12 weeks).
Conclusion:
AST was effective in treating Chronic Urticaria without side effects. There was a significant response in both ASST positive and negative groups.
Keywords: Chronic urticaria, Chronic autoimmune urticaria, Autologous serum skin test, Autologous serum therapy, Autologous whole blood, Urticaria total severity score.